Semax
A synthetic ACTH analog studied for BDNF and NGF upregulation, neuroprotection, and cognitive function in preclinical and clinical models.
Overview
Semax is a synthetic heptapeptide analog of the ACTH(4-7) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has been approved in Russia as a nasal spray for neurological applications including ischemic stroke, cognitive impairment, and optic nerve disease. Research has documented its ability to upregulate BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in CNS models, interact with dopaminergic and serotonergic systems, and provide neuroprotection in rodent ischemia paradigms. Its BDNF-upregulating mechanism is particularly relevant to synaptic plasticity and neuronal survival research.
Quick Reference
- Sequence
- Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
- Parent peptide
- ACTH(4-7) fragment
- Regulatory status
- Approved nasal spray in Russia for neurological indications
- Primary mechanism
- BDNF/NGF upregulation, melanocortin receptor signaling
- Purity standard
- >=98% by HPLC
How It Works
Semax acts through melanocortin receptor signaling and direct neurotrophic factor induction. It upregulates BDNF and NGF gene expression in hippocampal and cortical tissue in preclinical models, with documented interactions with dopaminergic and serotonergic neurotransmitter systems. Its proline-rich C-terminal extension contributes to its metabolic stability and CNS activity compared to the ACTH(4-7) parent fragment.
Research Highlights
Key findings from the published preclinical literature.
BDNF Upregulation in CNS Models
Preclinical studies have documented significant BDNF mRNA and protein upregulation in hippocampal tissue following Semax administration, with effects on synaptic plasticity-related gene networks and neuronal survival markers.
Neuroprotection in Ischemia Paradigms
Rodent middle cerebral artery occlusion (MCAO) models have examined Semax for its ability to reduce infarct volume and improve neurological outcomes, with mechanisms attributed to BDNF induction and anti-inflammatory signaling.
Cognitive Performance in Animal Models
Learning and memory task performance studies in rodents have documented improvements in spatial memory and attention metrics following Semax administration, consistent with its documented neurotrophic factor upregulation effects.
Clinical Use in Russian Neurology
Semax has been approved and used as a registered nasal spray medication in Russia for ischemic stroke, optic nerve disease, and cognitive support, providing one of the few instances of peptide-based neurotrophic compound regulatory approval globally.
Research Connections
Related research areas, stacks, and comparisons involving this compound.
Research Use Cases
Research Stacks
Compound Comparisons
Frequently Asked Questions
Source This Compound
Semax is available from Spartan Peptides at a minimum 98% HPLC-verified purity with batch-specific certificate of analysis. Domestic US supply, same-day dispatch before 2 PM EST. For in-vitro research use only.
All compounds are strictly for in-vitro research use only and not intended for human consumption.